ZOETIS INC.
ZTSZoetis Inc. (ZTS) is a global leader in animal health, providing a wide range of pharmaceutical, vaccine, and diagnostic products for livestock and companion animals. Established in 1952 and becoming an independent company in 2013, Zoetis develops innovative solutions to improve animal health and well-being, supporting the needs of veterinarians, pet owners, and livestock producers worldwide.
Dividend History
Investors can expect a dividend payout of $0.53 per share, scheduled to be distributed in 39 days on September 1, 2026
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| September 1, 2026 | $0.53 | 2026-07-20 | 2026-07-20 |
| June 2, 2026 | $0.53 | 2026-04-20 | 2026-04-20 |
| March 3, 2026 | $0.53 | 2026-01-20 | 2026-01-20 |
| December 2, 2025 | $0.50 | 2025-10-31 | 2025-10-31 |
| September 3, 2025 | $0.50 | 2025-07-18 | 2025-07-18 |
Dividends Summary
- Consistent Payer: ZOETIS INC. has rewarded shareholders with 54 dividend payments over the past 13 years.
- Total Returned Value: Investors who held ZTS shares during this period received a total of $12.70 per share in dividend income.
- Latest Payout: The most recent dividend of $0.53/share was paid 52 days ago, on June 2, 2026.
- Yield & Schedule: ZTS currently pays dividends quarterly with an annual yield of 2.80%.
- Dividend Growth: Since 2013, the dividend payout has grown by 715.4%, from $0.07 to $0.53.
- Dividend Reliability: ZTS has maintained or increased its dividend for 52 consecutive payments.
Company News
A securities class action lawsuit has been filed against Zoetis Inc. for allegedly making false and misleading statements about its Companion Animal products during January 2025 to May 2026. The lawsuit claims the company failed to disclose weakening veterinarian adoption of its Librela pain treatment following FDA safety warnings, significant ma...
A class action lawsuit has been filed against Zoetis, Inc. for allegedly making materially false statements and failing to disclose material adverse facts during the period from January 14, 2025 to May 6, 2026. The complaint alleges that Zoetis concealed weakening veterinarian adoption of its Librela product due to FDA safety warnings, significan...
A securities fraud class action lawsuit has been filed against Zoetis Inc. for allegedly making materially false statements and failing to disclose material adverse facts about its business. The lawsuit covers investors who purchased Zoetis securities between January 14, 2025 and May 6, 2026. The company's stock declined significantly following t...
A securities class action lawsuit has been filed against Zoetis Inc. for allegedly making false and misleading statements about its Companion Animal products during the period from January 14, 2025 to May 6, 2026. The lawsuit claims the company failed to disclose weakening veterinarian adoption of its Librela pain treatment following FDA safety w...
A securities fraud class action lawsuit has been filed against Zoetis Inc. for allegedly making materially false statements about product adoption during the class period of January 14, 2025 through May 6, 2026. The lawsuit alleges the company misrepresented the performance of key products including Librela, Simparica Trio, Apoquel, and Cytopoint...
